GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Altimmune Inc (STU:3G0) » Definitions » EV-to-Revenue

Altimmune (STU:3G0) EV-to-Revenue : 12,840.70 (As of Jun. 01, 2025)


View and export this data going back to 2017. Start your Free Trial

What is Altimmune EV-to-Revenue?

EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Altimmune's enterprise value is €256.81 Mil. Altimmune's Revenue for the trailing twelve months (TTM) ended in Mar. 2025 was €0.02 Mil. Therefore, Altimmune's EV-to-Revenue for today is 12,840.70.

The historical rank and industry rank for Altimmune's EV-to-Revenue or its related term are showing as below:

STU:3G0' s EV-to-Revenue Range Over the Past 10 Years
Min: -9290.26   Med: 29.85   Max: 9807.26
Current: 14608.6

During the past 13 years, the highest EV-to-Revenue of Altimmune was 9807.26. The lowest was -9290.26. And the median was 29.85.

STU:3G0's EV-to-Revenue is ranked worse than
99.5% of 997 companies
in the Biotechnology industry
Industry Median: 7.44 vs STU:3G0: 14608.60

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

As of today (2025-06-01), Altimmune's stock price is €4.779. Altimmune's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2025 was €0.00. Therefore, Altimmune's PS Ratio for today is .


Altimmune EV-to-Revenue Historical Data

The historical data trend for Altimmune's EV-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Altimmune EV-to-Revenue Chart

Altimmune Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
EV-to-Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 25.03 42.34 -9,199.76 1,403.69 19,572.76

Altimmune Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
EV-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1,317.76 756.50 5,751.81 19,572.76 12,044.30

Competitive Comparison of Altimmune's EV-to-Revenue

For the Biotechnology subindustry, Altimmune's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Altimmune's EV-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Altimmune's EV-to-Revenue distribution charts can be found below:

* The bar in red indicates where Altimmune's EV-to-Revenue falls into.


;
;

Altimmune EV-to-Revenue Calculation

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

Altimmune's EV-to-Revenue for today is calculated as:

EV-to-Revenue=Enterprise Value (Today)/Revenue (TTM)
=256.814/0.02
=12,840.70

Altimmune's current Enterprise Value is €256.81 Mil.
Altimmune's Revenue for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.02 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Altimmune  (STU:3G0) EV-to-Revenue Explanation

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

Altimmune's PS Ratiofor today is calculated as:

PS Ratio=Share Price (Today)/Revenue per Share (TTM)
=4.779/0
=

Altimmune's share price for today is €4.779.
Altimmune's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.00.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Altimmune EV-to-Revenue Related Terms

Thank you for viewing the detailed overview of Altimmune's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Altimmune Business Description

Traded in Other Exchanges
Address
910 Clopper Road, Suite 201S, Gaithersburg, MD, USA, 20878
Altimmune Inc is a clinical-stage biopharmaceutical company focused on developing treatments for obesity, metabolic diseases, and liver diseases. Its product candidate, pemvidutide (formerly known as ALT-801), is a novel, investigational, peptide-based GLP-1/glucagon dual receptor agonist. Pemvidutide is currently in clinical development for obesity and metabolic-associated steatohepatitis (MASH). The company also plans to pursue additional indications for pemvidutide that leverage the differentiated clinical profile of pemvidutide.

Altimmune Headlines

No Headlines